片仔癀(600436) - 2018 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 44.07% to CNY 326,118,301.78 year-on-year[5] - Operating revenue increased by 42.06% to CNY 1,222,189,418.52 compared to the same period last year[5] - Basic earnings per share increased by 42.11% to CNY 0.54[5] - The weighted average return on equity increased by 1.33 percentage points to 7.61%[5] - The company achieved operating revenue of 122,218.94 million yuan in Q1 2018, an increase of 36,186.91 million yuan or 42.06% compared to Q1 2017[13] - Operating profit for the quarter was ¥383,327,203.79, representing a 46.5% increase compared to ¥261,571,462.10 in Q1 2017[25] - The company reported a total comprehensive income of ¥302,216,434.14, up 37.0% from ¥220,577,172.18 in the same quarter last year[26] Assets and Liabilities - Total assets increased by 7.67% to CNY 6,081,749,590.65 compared to the end of the previous year[5] - Total current liabilities increased to ¥1,283,639,621.30 from ¥1,151,442,124.22, representing an increase of approximately 11.5%[21] - Total assets reached ¥4,690,400,706.27, up from ¥4,336,618,942.24, indicating a growth of about 8.2%[23] - Total liabilities amounted to ¥1,350,969,149.30, up from ¥1,223,043,435.38, which is an increase of about 10.4%[21] - Total equity increased to ¥4,730,780,441.35 from ¥4,425,234,007.20, showing a growth of approximately 6.9%[21] Cash Flow - Cash flow from operating activities decreased by 12.80% to CNY 241,767,161.18 compared to the previous year[5] - The net cash flow from operating activities for the first quarter of 2018 was ¥266,259,836.94, slightly down from ¥270,121,072.38, a decrease of 1.4%[31] - Cash flow from financing activities generated a net inflow of ¥63,823,718.81, compared to a net outflow of ¥303,929,183.31 in the previous period[30] - The total cash and cash equivalents at the end of the period increased to ¥1,901,419,693.29 from ¥1,266,467,718.98, marking a rise of 50%[30] Expenses - Operating costs for the period were 65,404.40 million yuan, up 17,893.88 million yuan or 37.66% year-on-year, primarily due to increased sales in the pharmaceutical industry[14] - The company reported a significant increase in sales expenses, totaling 10,835.94 million yuan, which is an increase of 3,451.15 million yuan or 46.73% year-on-year, driven by business expansion efforts[14] - The company’s tax and additional charges amounted to 1,440.67 million yuan, an increase of 443.30 million yuan or 44.45% year-on-year, attributed to higher sales revenue[14] - Financial expenses surged to 248.03 million yuan, reflecting a 381.42% increase due to higher bank borrowings and interest expenses[15] Investment and Other Income - The company recorded a decrease in investment income to 345.58 million yuan, down 542.07 million yuan or 61.07% compared to the previous year[16] - Investment income decreased to ¥3,455,808.02 from ¥8,876,482.48, a decline of 61.0% year-over-year[25] - Other comprehensive income decreased to ¥98,519,441.43 from ¥121,780,899.20, indicating a decline of approximately 19.1%[21] - Other comprehensive income after tax was -¥23,362,765.33, compared to ¥1,089,664.59 in Q1 2017, indicating a significant decline[25]